Nama's AI scorecard currently rates Tandem Diabetes Care Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does TNDM report earnings?

Tandem Diabetes Care's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $0.16.

What is the TNDM price target?

The median analyst price target from 21 analysts is $26.00, with a range of $18.00 – $50.00.

Is TNDM Shariah compliant?

Nama's AAOIFI-style screen reads Tandem Diabetes Care as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Tandem Diabetes Care (TNDM)

Healthcare · Medical Devices · NASDAQ

Tandem Diabetes Care (TNDM) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.18B and a free-cash-flow yield of -9.5%. Over the most recent reported fiscal year, revenue grew 7.9% and free cash flow per share fell 2208.7%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Middle · +18.8% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-89.2%

How far the last close sits under the highest price of the past five years.

Market cap	$1.18B
Trailing P/E	—
Price / book	9.0
Price / sales	1.1
FCF yield	-9.5%
Dividend yield	—
Gross margin	56.0%
Operating margin	-4.4%
Net margin	-6.1%
Revenue growth (YoY)	+7.9%
Revenue growth (3-yr annual)	+8.2%
EPS growth (YoY)	—
FCF/share growth (YoY)	-2208.7%
Beta	1.7
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

TNDM earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate $0.16). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.10	-$0.24	+58.3%	—
Q2 2026	Aug 6, 2026	-$0.31	-$0.32	+3.1%	$254.56M
Q1 2026	May 7, 2026	-$0.30	-$0.44	+31.8%	$247.22M
Q4 2025	Feb 19, 2026	-$0.01	-$0.09	+88.9%	$290.38M

TNDM analyst price target

Median target $26.00 from 21 analysts, ranging $18.00 – $50.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live TNDM data on Nama Insights →

Recent Congressional trades

Tandem Diabetes Care trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Josh Gottheimer	House	Buy	$1,001 - $15,000	Oct 15, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Apr 10, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2025
Josh Gottheimer	House	Buy	$1,001 - $15,000	Sep 11, 2024

TNDM FAQ

Is TNDM a buy?: Nama's AI scorecard currently rates Tandem Diabetes Care Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does TNDM report earnings?: Tandem Diabetes Care's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $0.16.
What is the TNDM price target?: The median analyst price target from 21 analysts is $26.00, with a range of $18.00 – $50.00.
Is TNDM Shariah compliant?: Nama's AAOIFI-style screen reads Tandem Diabetes Care as Not Shariah Compliant. At least one of the three ratios or the industry test failed.